Invesco Ltd. Has $1.18 Million Stock Position in Bausch Health Companies Inc. (NYSE:BHC)

Invesco Ltd. trimmed its position in Bausch Health Companies Inc. (NYSE:BHC) by 5.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 146,837 shares of the company’s stock after selling 8,432 shares during the quarter. Invesco Ltd.’s holdings in Bausch Health Companies were worth $1,184,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in shares of Bausch Health Companies by 20.5% during the third quarter. Geode Capital Management LLC now owns 636,082 shares of the company’s stock worth $6,448,000 after buying an additional 108,269 shares in the last quarter. Range Financial Group LLC bought a new stake in shares of Bausch Health Companies during the 4th quarter worth approximately $1,004,000. Sanders Morris Harris LLC grew its position in shares of Bausch Health Companies by 16.0% in the 4th quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company’s stock valued at $234,000 after acquiring an additional 4,000 shares during the period. Merit Financial Group LLC acquired a new position in shares of Bausch Health Companies during the 4th quarter worth about $228,000. Finally, SG Americas Securities LLC lifted its stake in Bausch Health Companies by 62.0% in the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock valued at $26,614,000 after purchasing an additional 1,263,706 shares during the last quarter. 78.65% of the stock is owned by institutional investors.

Bausch Health Companies Stock Performance

Shares of NYSE BHC opened at $5.29 on Friday. The stock has a fifty day moving average of $6.10 and a 200-day moving average of $7.24. The stock has a market cap of $1.95 billion, a PE ratio of -44.04, a price-to-earnings-growth ratio of 0.37 and a beta of 0.43. Bausch Health Companies Inc. has a fifty-two week low of $3.96 and a fifty-two week high of $9.85.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.44). The company had revenue of $2.56 billion for the quarter, compared to analysts’ expectations of $2.51 billion. Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. On average, sell-side analysts predict that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on BHC. Jefferies Financial Group reaffirmed a “hold” rating and issued a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. Royal Bank of Canada dropped their price objective on shares of Bausch Health Companies from $9.00 to $8.50 and set a “sector perform” rating for the company in a research note on Monday, April 7th. Finally, StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $7.17.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.